Mehra, MR. 5-Year Survival with LVAD Therapy in MOMENTUM 3. Presented at: European Society of Cardiology (ESC) Annual Meeting; August 28, 2022; Barcelona, Spain.
This extension of the MOMENTUM 3 study extended out 5 years and showed the superior treatment effect of the HeartMate 3 LVAD over HeartMate II LVAD on HRAEs, which was associated with improved survival at 5-years:
MAT-2210315 v2.0
Stay Connected